Effect of prostaglandin E in multiple experimental models. VII. Effect on resistance to sepsis*

US Army Institute of Surgical Research, Fort Sam Houston, San Antonio, Texas, USA

The immunosuppression seen following burn injury has frequently been attributed to elevated prostaglandin E levels. We evaluated the contribution of elevated prostaglandin E levels on susceptibility to infectious complications utilizing multiple mouse models. The administration of 100 pg/kg of the long-acting derivative of prostaglandin E, 16,16-dimethyl-prostaglandin E, was found to improve survival in C3/HEN mice challenged with 1 x 10^9 Escherichia coli organisms intraperitoneally. The administration of indomethacin was found to decrease survival to the same model. With C3/HEN (endotoxin-resistant) mice, indomethacin was found to increase mortality rates in animals challenged with 1 x 10^9, 1 x 10^10 or 1 x 10^11 Escherichia coli organisms. These findings suggest that elevated prostaglandin E levels seen in burn patients may not be responsible for the postburn increased susceptibility to infectious complications.

**Introduction**

One of the primary etiologies for mortality following burn injury is the development of infectious complications (Sevitt, 1979). These infections have two main causes, a loss of the skin's natural barrier and the immunosuppression that results from burn injury. This immunosuppression is due to a number of factors, including inadequate nutrition in the postburn period, the use of immunosuppressive agents such as anaesthesia and blood transfusions, and the release of endogenous immunosuppressive metabolites.

Prostaglandin E (PGE) has been reported to be one of the immunosuppressive metabolites released following burn injury (Ninnemann and Stockland, 1984). The belief in an immunosuppressive nature of PGE has resulted from two areas of investigation. The first is the demonstration by Arturson (1976) that PGE levels are increased following burn injury and that burn patients are immunosuppressed (Warden, 1986). The second is the demonstration that PGE impairs immune function in a number of in vitro leucocyte culture models (Faist et al., 1987).

*The opinions or assertions contained herein are the private views of the authors and not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense.

The care of all animals was in accordance with the guidelines set forth by the Animal Welfare Act and other Federal statutes and regulations relating to animals and studies involving animals and with the Guide for the Care and Use of Laboratory Animals, National Institutes of Health Publication 86-23.

© 1990 Butterworth & Co (Publishers) Ltd
0305-4179/90/010009-04

**Materials and methods**

**Animals**

Five hundred adult male C3/HEJ mice and 210 adult male C3/HEN mice weighing approximately 25 g were used in these studies. The mice were housed in stainless-steel hanging cages and allowed food and water ad libitum. The mice were observed for a minimum of 1 week prior to entry into the study to exclude the presence of pre-existing diseases.

**Drugs**

The dPGE was generously supplied by the Upjohn Company (Kalamazoo, MI, USA). The dPGE was diluted with sufficient normal saline to achieve a concentration that permitted the desired dose of drug to be administered in a final volume of 0.25 ml. The dPGE was injected intraperitoneally through a 25-gauge needle.

Indomethacin was generously supplied by Merck Sharp & Dohme (Columbus, OH, USA). The indomethacin was also diluted with sufficient normal saline to achieve a final concentration that permitted the desired dose to be administered in a final volume of 0.25 ml. The indomethacin was injected intraperitoneally through a 25-gauge needle.

**Sepsis models**

Six sepsis models were chosen, all of which utilized intraperitoneal injections of varying quantities of Escherichia coli organisms. The E. coli were cultured in trypticase soy broth at 37°C for 16 h and then centrifuged at 3000 rpm for 5 min. The supernatant was decanted and the E. coli pellet resuspended in a sufficient volume of saline to achieve the desired concentration of organisms. For the C3/HEN mice, two quantities of the E. coli were tested. For the first, 1 x 10^7 c.f.u. of the E. coli organisms were given intraperitoneally in a
volume of 0.5 ml saline. For the second, $1 \times 10^8$ c.f.u. of the E. coli were given in 0.5 ml of saline.

The E. coli organisms were administered at four concentrations to the C3/HEJ mice. For the first, $1 \times 10^7$ c.f.u. in 0.5 ml of saline were given. The second was $1 \times 10^6$ c.f.u. in 0.5 ml of saline. For the third, $1 \times 10^5$ c.f.u. in 0.5 ml of saline were given. The final concentration was $1 \times 10^4$ c.f.u. in 0.5 ml of saline.

In each of the peritonitis models, the mice were randomized to one of four drug treatment groups. The first received twice daily injections of 0.25 ml of normal saline intraperitoneally. The second received twice daily intraperitoneal injections of 4 mg/kg of indomethacin dissolved in 0.25 ml of saline. The third group received twice daily injections of 50 μg/kg of dPGE dissolved in 0.25 ml of saline intraperitoneally and the final group received twice daily injections of 100 μg/kg of dPGE dissolved in 0.25 ml of saline intraperitoneally. Table I lists the number of animals in each drug treatment group for each of the models.

With each model, the mice were followed for 7 days after peritoneal challenge to determine mean survival times and absolute survival rates. Those mice surviving to 7 days had had no further mortalities. For the calculation of mean survival times, the mice which survived 7 days were given a survival time of 7 days.

All data are presented as mean ± s.e.m. Comparisons among groups were performed using chi-square and Kruskal-Wallis tests.

**Results**

The C3/HEN mice challenged with $1 \times 10^7$ E. coli c.f.u. had a 100 per cent survival rate in the saline control group. The 50 μg/kg dPGE treated group and the 100 μg/kg dPGE treatment group (Table II). Those mice receiving indomethacin had a decreased survival rate of 16 per cent ($P<0.001$). The mean survival time for the indomethacin-treated mice was also significantly decreased when compared with the other groups ($P<0.0001$) (Table II).

For C3/HEN mice challenged with $1 \times 10^8$ E. coli c.f.u., the survival rates of the saline-treated and 50 μg/kg dPGE-treated groups were 8 per cent (Table II). The indomethacin treatment group had a 0 per cent survival rate and the mice treated with 100 μg/kg of dPGE had a survival rate of 32 per cent. These differences were statistically significant ($P<0.01$). The increased mean survival time of the mice treated with 100 μg/kg of dPGE (Table II) was also statistically significant when compared with the other groups ($P<0.005$).

The C3/HEJ mice injected with $1 \times 10^7$ E. coli c.f.u. had a 94 per cent survival rate in the saline treatment group (Table III). Both the 50 μg/kg and the 100 μg/kg dPGE treatment groups had an 84 per cent survival rate. The indomethacin-treated mice had a 76 per cent survival rate. These differences were not statistically significant. The differences in the mean survival times among these four groups were also not statistically significant (Table III).

---

**Table I. Number of mice used for each sepsis model (represented by colonies of E. coli) in each treatment group**

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>$1 \times 10^7$</th>
<th>$1 \times 10^6$</th>
<th>$1 \times 10^7$</th>
<th>$1 \times 10^6$</th>
<th>$1 \times 10^7$</th>
<th>$1 \times 10^6$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saline</td>
<td>25</td>
<td>25</td>
<td>50</td>
<td>25</td>
<td>50</td>
<td>25</td>
</tr>
<tr>
<td>Indomethacin</td>
<td>25</td>
<td>25</td>
<td>25</td>
<td>25</td>
<td>25</td>
<td>25</td>
</tr>
<tr>
<td>50 μg/kg dPGE</td>
<td>25</td>
<td>25</td>
<td>25</td>
<td>25</td>
<td>25</td>
<td>25</td>
</tr>
<tr>
<td>100 μg/kg dPGE</td>
<td>25</td>
<td>25</td>
<td>25</td>
<td>25</td>
<td>25</td>
<td>25</td>
</tr>
</tbody>
</table>

**Table II. Mean survival times (mean ± s.e.m.) and survival rates in C3/HEN mice challenged with $1 \times 10^7$ or $1 \times 10^8$ colonies of E. coli**

<table>
<thead>
<tr>
<th>Treatment group</th>
<th>Mean survival time (days)</th>
<th>Survival rate (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saline</td>
<td>7.00 ± 0.00</td>
<td>100</td>
</tr>
<tr>
<td>Indomethacin</td>
<td>2.88 ± 0.44</td>
<td>16</td>
</tr>
<tr>
<td>50 μg/kg dPGE</td>
<td>7.00 ± 0.00</td>
<td>100</td>
</tr>
<tr>
<td>100 μg/kg dPGE</td>
<td>7.00 ± 0.00</td>
<td>100</td>
</tr>
</tbody>
</table>

---

**Table III. Mean survival times (mean ± s.e.m.) and survival rates of C3/HEJ mice challenged with $1 \times 10^7$, $1 \times 10^6$, $1 \times 10^8$ and $1 \times 10^9$ colonies of E. coli**

<table>
<thead>
<tr>
<th></th>
<th>$1 \times 10^7$</th>
<th>$1 \times 10^6$</th>
<th>$1 \times 10^8$</th>
<th>$1 \times 10^9$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saline</td>
<td>6.72 ± 0.16</td>
<td>94</td>
<td>7.00 ± 0.00</td>
<td>100</td>
</tr>
<tr>
<td>Indomethacin</td>
<td>5.76 ± 0.46</td>
<td>76</td>
<td>4.84 ± 0.45</td>
<td>44</td>
</tr>
<tr>
<td>50 μg/kg dPGE</td>
<td>6.20 ± 0.38</td>
<td>84</td>
<td>7.00 ± 0.00</td>
<td>100</td>
</tr>
<tr>
<td>100 μg/kg dPGE</td>
<td>6.25 ± 0.25</td>
<td>84</td>
<td>7.00 ± 0.00</td>
<td>100</td>
</tr>
</tbody>
</table>

---

* $P<0.001$; ** $P<0.0001$.
For C3/HEJ mice challenged with $1 \times 10^8$ E. coli c.f.u., the indomethacin treatments significantly decreased both survival rates and mean survival times (Table III). The 44 per cent survival rate was statistically significant ($P < 0.001$), as was the 4.64 ± 0.45 day mean survival time ($P < 0.0001$) when compared with the saline and dPGE treatment groups.

The detrimental effect of indomethacin treatment was also demonstrated in the C3/HEJ mice challenged with $1 \times 10^8$ E. coli c.f.u. (Table III). Both the 4 per cent survival rate and the $3.28 \pm 0.26$ day mean survival time were statistically significant when compared with the other three groups ($P < 0.001$ for survival rates and $P < 0.0001$ for mean survival times).

Finally, at the $1 \times 10^9$ E. coli c.f.u. challenge, indomethacin treatment adversely affected survival in the C3/HEJ mice. With this quantity of bacterial challenge, the indomethacin-treated mice had a 16 per cent survival rate and a $3.68 \pm 0.40$ day mean survival time, which were both statistically significant when compared with remaining groups ($P < 0.001$ for survival rates and $P < 0.0001$ for mean survival times).

**Discussion**

Infection remains a major cause of morbidity and mortality following thermal injuries. The immunosuppression seen following thermal injuries is one of the main reasons for this elevated infection rate.

Elevated PGE levels have long been thought to be a contributing factor to the immunosuppression seen in burn patients because of the high levels demonstrated in burn patient serum and because of its toxic effects on leucocyte function in studies in vitro.

Attempts to quantify the contribution of PGE to the postburn immunosuppression have been thwarted by the extremely short half-life of parenterally administered PGE. To avoid this limitation, we have utilized a long-acting derivative of PGE (dPGE) to quantify the contribution of elevated PGE levels to susceptibility to infection-related mortality. We have previously reported that the administration of dPGE to Lewis rats increased survival rates in an E. coli peritonitis model (Waymack and Yurt, 1986). This beneficial effect appears due, at least in part, to its ability to decrease the release of tumour necrosis factor.

The results with C3/HEN (endotoxin-sensitive) mice demonstrated a protective effect of elevated PGE levels as evidenced by an increased survival in those animals receiving the dPGE and decreased survival among those receiving indomethacin. These findings strongly suggest that the previously demonstrated beneficial effect of dPGE administration in septic rats is not a species-specific response.

In C3/HEJ (endotoxin-resistant) mice, there was no significant mortality in the saline treatment group, even at the $1 \times 10^8$ c.f.u. of E. coli challenge. The ability of the strain of mouse to resist such a high concentration of E. coli organisms is probably due, at least in part, to its inability to synthesize the highly toxic macrophage metabolite tumour necrosis factor following the endotoxin exposure. As such, this prevented any possible demonstration of a beneficial effect of dPGE administration.

It was, however, noteworthy that indomethacin treatment of the C3/HEJ mice did result in a significant increase in survival in three of the E. coli peritonitis models. Since C3/HEJ mice are not capable of synthesizing tumour necrosis factor, the detrimental effect of indomethacin cannot be attributed to the PGE/tumour necrosis factor interaction which has previously been demonstrated in rats (Waymack et al., submitted (a)). The increased mortality rate in the indomethacin-treated mice may be due to the effect of indomethacin on blood flow to various organs, on release of other toxic compounds of leucocytes in response to bacterial endotoxin exposure, or on the inhibition of the normal physiological response to sepsis. Such an inhibition has previously been demonstrated in burned septic rats treated with the cyclo-oxygenase inhibitor ibuprofen (Waymack, 1989). The rats which received ibuprofen in that study failed to show the normal hypermetabolic response to sepsis and had a significantly higher mortality rate when compared to the rats treated with saline. Fink et al. (1984) reported that the use of cyclo-oxygenase inhibitors prevented the normal hyperdynamic response in septic dogs. When one considers the increased physiological workload septic patients must accomplish, the benefits of preventing a hyperdynamic/hypermetabolic state must be questioned. Further studies will be required to determine the contribution of these factors to the increased mortality rate.

In conclusion, the elevation of PGE levels seen in burn patients may be a normal physiological response of the body to protect against infection-related mortality which is common in burn patients. Attempts to decrease the rate of PGE synthesis in the burn patient through the use of cyclo-oxygenase inhibitors may only increase the mortality rate in those patients who develop infections. Further studies delineating the physiological importance of PGE in sepsis should be undertaken prior to initiation of trials using cyclo-oxygenase inhibitors in septic patients.

**References**


Fink M. P., MacVittie T. J. and Casey L. C. (1984) Inhibition of prostaglandin synthesis restores normal hemodynamics in


Correspondence should be addressed to: Dr. J. P. Waymack, US Army Institute of Surgical Research, Fort Sam Houston, San Antonio, TX 78234-5012, USA.

---

Tanner-Vandeput Prize for Burn Research 1990 Award

The 1990 Tanner-Vandeput Prize for Burn Research, consisting of a cash payment, will be awarded at the 8th International Congress on Burn Injuries of the ISBI, to be held November 11-16, 1990 in New Delhi, India. The Prize will go to a person or person who, in the opinion of the Prize Committee, has made a substantial and outstanding contribution to any aspect of the burn field in their lifetime (i.e., a 'senior investigator's' award). The recipient does not have to be a member of the ISBI or a physician, but be responsible for a major advancement in the treatment of burns.

Nominations for the 1990 Prize may be made by colleagues of those who have made such a contribution to burn care in their lifetime. A candidate may also make an application on his own behalf.

Anyone interested in applying for the 1990 Tanner-Vandeput Prize for Burn Research should send the following information to the ISBI Secretary-General at the address below.

Information required to apply for the Tanner-Vandeput Prize for 1990:
- Letter of nomination (can be sent by candidate or by someone else)
- Description of work, including samples and documentation
- Current Curriculum Vitae
- Letters of support from colleagues

Send five copies of this information to:
Dr. John A. Boswick,
International Society for Burn Injuries,
2005 Franklin St. #460,
Denver, Colorado 80205, USA. Tel (303) 839-1694.

Deadline for receipt of applications: July 31, 1990.

Information regarding the Tanner-Vandeput prize for burn research

The Prize was established in 1984 by Dr. J. C. Tanner of Atlanta, Georgia, co-inventor with Dr. Jacques Vandeput of the Tanner-Vandeput Mesh Dermatome. This Prize was conceived and established to promote the aims of the International Society for Burn Injuries and to motivate individual investigators to do research, study, undertake patient care and treatment and other aspects of the burn problem, and will be awarded to one who has made a substantial contribution to burn care in their lifetime (a 'senior investigator's' award). The Prize consists of a cash payment.

A foundation was created for the sole purpose of awarding the Prize every four years and has separate funds invested to produce income used for the Prize. A trust fund is owned by the 'International Burn Foundation of the United States,' an organization entirely separate from the ISBI. The funds do not overlap or mingle in any way with those of the ISBI.

The only role the ISBI plays in the Tanner-Vandeput Prize is to coordinate and award the Prize for each Quadrennial Congress. The International Burn Foundation has a Board of Directors and a Prize Committee which reviews applications and makes recommendations for award of each Prize.

The Prize Committee voted to award the first Tanner-Vandeput Prize, presented at the 7th International Congress held February 1986 in Melbourne, Australia to Dr Ian Alan Holder of the Shriners Burns Institute in Cincinnati, Ohio for his work on 'Infection by Pseudomonas Aeruginosa.' He was presented with a cash payment and a gold and diamond lapel pin signifying his achievement.